Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. Files DC, Tacke F, O'Sullivan A, Dorr P, et al. PLoS Pathog 2022;18:e1010547.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Files DC, Tacke F, O'Sullivan A, Dorr P, et al. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS Pathog 2022;18:e1010547.
PMID: 35749425